Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | 0.16 | -0.04 | 0.01 |
| FCF Yield | 1.29% | -6.09% | 6.50% | -1.21% |
| EV / EBITDA | 22.14 | -3.14 | 2.48 | -0.88 |
| Quality | ||||
| ROIC | 8.00% | -3.35% | 31.01% | -108.34% |
| Gross Margin | 77.74% | 77.38% | 79.81% | 88.97% |
| Cash Conversion Ratio | 0.64 | 1.09 | 0.35 | 0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.12% | 26.57% | 27.50% | 2,381,765.64% |
| Free Cash Flow Growth | 192.63% | -155.29% | 819.24% | -109.41% |
| Safety | ||||
| Net Debt / EBITDA | -3.56 | 18.91 | -2.71 | 1.16 |
| Interest Coverage | 2.42 | -17.11 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | -0.00 | -0.00 | -0.01 | 0.00 |
| Cash Conversion Cycle | -119,184.34 | -114,020.91 | -49,862.19 | -156.09 |